These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20368235)

  • 61. Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.
    Bittner V; Bertolet M; Barraza Felix R; Farkouh ME; Goldberg S; Ramanathan KB; Redmon JB; Sperling L; Rutter MK;
    J Am Coll Cardiol; 2015 Aug; 66(7):765-773. PubMed ID: 26271057
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
    Sobel BE; Frye R; Detre KM;
    Circulation; 2003 Feb; 107(4):636-42. PubMed ID: 12566379
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Optimal care of patients with type 2 diabetes mellitus and coronary artery disease.
    Frye RL
    Am J Med; 2003 Dec; 115 Suppl 8A():93S-98S. PubMed ID: 14678873
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.
    Pop-Busui R; Lu J; Brooks MM; Albert S; Althouse AD; Escobedo J; Green J; Palumbo P; Perkins BA; Whitehouse F; Jones TL;
    Diabetes Care; 2013 Oct; 36(10):3208-15. PubMed ID: 23757426
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes.
    Marx N
    Diab Vasc Dis Res; 2008 Nov; 5(4):345-6. PubMed ID: 18958845
    [No Abstract]   [Full Text] [Related]  

  • 66. Clinical studies on coronary revascularization in patients with type 2 diabetes.
    Mak KH; Faxon DP
    Eur Heart J; 2003 Jun; 24(12):1087-103. PubMed ID: 12804923
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Treatment of stable coronary artery disease in type II diabetes mellitus: drugs, coronary intervention and bypass surgery].
    Schneider CA; Pfister R
    Dtsch Med Wochenschr; 2015 Apr; 140(9):657-62. PubMed ID: 25924045
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D.
    Zonszein J; Lombardero M; Ismail-Beigi F; Palumbo P; Foucher S; Groenewoud Y; Cushing G; Wajchenberg B; Genuth S;
    J Diabetes Res; 2015; 2015():129891. PubMed ID: 26106623
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gap between clinical trials and clinical practice: lessons from the Bypass Angioplasty Revascularization Investigation (BARI).
    Frye RL; Brooks MM; Nesto RW;
    Circulation; 2003 Apr; 107(14):1837-9. PubMed ID: 12695282
    [No Abstract]   [Full Text] [Related]  

  • 70. Coronary artery disease and diabetes mellitus.
    Aronson D; Edelman ER
    Cardiol Clin; 2014 Aug; 32(3):439-55. PubMed ID: 25091969
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A perspective on coronary revascularization in the PROactive 05 study.
    Riche DM; Dale KM
    J Am Coll Cardiol; 2007 Oct; 50(17):1705-6; author reply 1706. PubMed ID: 17950157
    [No Abstract]   [Full Text] [Related]  

  • 72. Modifications of coronary risk factors.
    Albu J; Gottlieb SH; August P; Nesto RW; Orchard TJ;
    Am J Cardiol; 2006 Jun; 97(12A):41G-52G. PubMed ID: 16813737
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Do Clinical Outcomes and Quality of Life Differ by the Number of Antianginals for Stable Ischemic Heart Disease? Insights from the BARI 2D Trial.
    Jamil Y; Park DY; Verde LM; Sherwood MW; Tehrani BN; Batchelor WB; Frampton J; Damluji AA; Nanna MG
    Am J Cardiol; 2024 Mar; 214():66-76. PubMed ID: 38160927
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Levels of evidence needed for changing indications, contraindications, and Food and Drug Administration labeling: the case of metformin.
    Eurich DT; Majumdar SR; McAlister FA; Tsuyuki RT; Johnson JA
    Arch Intern Med; 2011 Jun; 171(11):1042-3; author reply 1043. PubMed ID: 21670379
    [No Abstract]   [Full Text] [Related]  

  • 75. Seeking alternatives to Hard End Points: is imaging the best APPROACH?
    Finn AV; Chandrashekhar Y; Narula J
    Circulation; 2010 Mar; 121(10):1165-8. PubMed ID: 20194886
    [No Abstract]   [Full Text] [Related]  

  • 76. Medical management of the diabetic patient with coronary artery disease.
    Karastergiou K; Kaski JC
    Curr Pharm Des; 2008; 14(25):2527-36. PubMed ID: 18991670
    [TBL] [Abstract][Full Text] [Related]  

  • 77. BARI 2D: headlines are not enough.
    King SB
    JACC Cardiovasc Interv; 2009 Aug; 2(8):809-10. PubMed ID: 19695556
    [No Abstract]   [Full Text] [Related]  

  • 78. Rosiglitazone and cardiovascular outcomes: is there a clear answer?
    Gerstein HC
    Circulation; 2013 Aug; 128(8):777-9. PubMed ID: 23857319
    [No Abstract]   [Full Text] [Related]  

  • 79. Implications of randomized studies of medical therapy vs revascularization for reducing rising costs of health care.
    Beller GA
    J Nucl Cardiol; 2009; 16(4):483-5. PubMed ID: 19562423
    [No Abstract]   [Full Text] [Related]  

  • 80. Ischemia dictates outcome, not symptoms.
    Stone PH
    J Am Coll Cardiol; 2013 Feb; 61(7):712-3. PubMed ID: 23410542
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.